RXSTHealthcare · Medical DevicesThe 10 Wall Street analysts covering RxSight, Inc. hold a median 12-month price target of $6.65 — +36.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores RxSight, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (70): The business earns solid, repeatable profits on what it owns.
Momentum (13): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RXST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +36.6% from it.
Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Sept 2026 | B of A Securities | Maintains | Underperform | $6.50 → $5.50 |
| 22 Sept 2026 | Jefferies | Maintains | Hold | $6.50 → $5.75 |
| 10 Aug 2026 | Stifel | Maintains | Hold | $8.00 → $7.00 |
| 10 Aug 2026 | Stifel | Maintains | Hold | — |
| 6 Aug 2026 | UBS | Maintains | Neutral | $5.50 → $6.30 |
| 6 Aug 2026 | UBS | Maintains | Neutral | — |
| 28 July 2026 | UBS | Assumes | Neutral | $9.00 → $5.50 |
| 7 July 2026 | B of A Securities | Maintains | Underperform | $8.00 → $6.50 |
| 7 July 2026 | B of A Securities | Maintains | Underperform | — |
| 7 July 2026 | Needham | Reiterates | Buy | $11 |
| 7 July 2026 | Needham | Reiterates | Buy | — |
| 7 May 2026 | Needham | Maintains | Buy | — |
| 7 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 Mar 2026 | Stifel | Maintains | Hold | — |
| 26 Feb 2026 | Needham | Reiterates | Buy | — |
| 26 Feb 2026 | Piper Sandler | Maintains | Neutral | — |
| 26 Feb 2026 | UBS | Maintains | Neutral | — |
| 20 Jan 2026 | Piper Sandler | Maintains | Neutral | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 Nov 2025 | JP Morgan | Maintains | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RXST appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, RxSight, Inc. returned −43.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 57% of US stocks
Cheaper than 76% of US stocks
Cheaper than 64% of US stocks
Higher than 28% of US stocks
Higher than 37% of US stocks
Higher than 88% of US stocks
Higher than 18% of US stocks
Higher than 12% of US stocks
Higher than 32% of US stocks
Higher than 26% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
RxSight, Inc. has a market value of $202.6M and an enterprise value of $11.8M.
Revenue in the twelve months to 30 June 2026: $127.6M. The latest quarter grew 0.3% year on year.
Net income over the same four quarters: −$46.9M, a −36.8% net margin.
Diluted earnings per share, trailing twelve months: $−1.13.
Free cash flow in the twelve months to 30 June 2026: −$27.2M.
Trailing P/E: −5.1×; forward P/E: −7.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
RxSight, Inc. employs 461 people — $277K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own RxSight, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
RxSight granted inducement stock options for 236,456 shares to two new non-executive officer employees and agreed to grant them RSUs covering 637,449 shares, anticipated around November 3, 2026.
Why it matters — The grants are a share-based compensation commitment associated with the employees’ commencement of employment.
RxSight announced it will report third-quarter 2026 financial results after market close on November 3, 2026. Management will discuss the results on a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Why it matters — RXST watchers can note the scheduled date and time for the company's upcoming financial results and management discussion.
RxSight announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy.
Why it matters — The appointments add commercial leadership roles at RxSight, a development relevant to watchers of the company’s commercial operations.
K2 Vision has performed more than 5,000 Light Adjustable Lens procedures and is recognized by RxSight as the world’s highest-volume LAL practice.
Why it matters — The recognition highlights use of RxSight’s Light Adjustable Lens at a high-volume practice.
RxSight, Inc. announced it will participate in the Wells Fargo Healthcare Conference on September 9, 2026 in Boston. A live and archived webcast will be available on the company's investor relations website.
Why it matters — The company's participation gives RXST watchers an opportunity to hear management's presentation, which may offer insight into the company's outlook during an investor event.
The 10 Wall Street analysts covering RxSight, Inc. have a median 12-month price target of $6.65, with estimates ranging from $5.5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering RxSight, Inc., 1 rate it a Buy, 7 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks RxSight, Inc. 41 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, RxSight, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (70 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +36.6% from the last close, and Ticker Nerd's factor model ranks RxSight, Inc. 41 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering RxSight, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RXST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.5 to $11 over the next 12 months.
RxSight, Inc. returned -43.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery.
The most recent item we track (GlobeNewsWire, 24 Oct 2026): "RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules". RxSight granted inducement stock options for 236,456 shares to two new non-executive officer employees and agreed to grant them RSUs covering 637,449 shares, anticipated around November 3, 2026.
RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery. The company’s core offering is the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens and the Light Delivery Device, along with related accessories used by eye care professionals. This platform allows doctors to customize and optimize a patient’s visual acuity after implantation, addressing a major need in premium cataract care. RxSight serves ophthalmic surgeons, ambulatory surgery centers, and ophthalmology practices, with its products used in the U.S. cataract surgery market and selected international markets through distribution partners. Headquartered in Aliso Viejo, California, RxSight operates as a specialized medical device business centered on adjustable intraocular lens technology and post-surgical vision refinement.
CEO Mr. Aziz Mottiwala M.B.A. · 461 employees · United States · https://rxsight.com
